Nuvelo to be Featured at the Third Annual JMP Securities Research Conference SUNNYVALE, Calif., March 4 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO; interim ticker symbol: NUVOD) today announced that Ted W. Love, M.D., president and CEO, will be presenting at the Third Annual JMP Securities Research Conference in San Francisco, California, on Tuesday, March 9, 2004 at 2:50 p.m. Pacific Time. Dr. Love will provide a brief corporate overview and discuss the company's recently expanded pipeline and near-term milestones. A live audio webcast of the presentation will be available online via the Investor Relations portion of Nuvelo's Web site at http://www.nuvelo.com/ or at http://w.on24.com/r.htm?e=5221&s=1&k=A588DCA3E7E830DE49B14E0B4B4A2811 . About Nuvelo Nuvelo, Inc. is engaged in the discovery, development and commercialization of life improving therapeutics for the treatment of human disease. Nuvelo's lead product candidate, alfimeprase, is partnered with Amgen and is currently in two Phase 2 trials in two indications, peripheral arterial occlusion and catheter occlusion. Additional programs include cardiovascular product candidates ARC183 and rNAPc2 and drug discovery focused on antibody targets and secreted proteins. Information about Nuvelo is available at our new Web site at http://www.nuvelo.com/ or by phoning 408-215-4000. DATASOURCE: Nuvelo, Inc. CONTACT: Pete Garcia, Sr. VP and Chief Financial Officer, +1-408-215-4574, or , or Nicole Estrin, Manager of Corporate Communications & IR, +1-408-215-4572, or , both of Nuvelo, Inc. Web site: http://www.nuvelo.com/

Copyright